Search - tctmd.com

Displaying 61 - 80 of 122

Sort: Relevancy | Date

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

Shelley Wood

December 30, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Conference News AHA 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

Todd Neale

November 07, 2022

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2022

Shelley Wood

September 01, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

News Conference News ESC Heart Failure 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

Advertisement

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Vast Majority of HFrEF Patients Eligible for Vericiguat

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

The Biggest News of 2022: TCTMD’s Top 10

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

CV Care Around Noncardiac Surgery: New ESC Guidelines

TCTMD’s Top 10 Most Popular Stories for August 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

What’s Going to Be Hot at ESC 2022?

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content